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Introduction: ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13)
deficiency has been reported in patients with sepsis but its clinical relevance and pathophysiology remain unclear.
Our objectives were to assess the clinical significance, prognostic value and pathophysiology of ADAMTS13
deficiency in patients with septic shock with and without disseminated intravascular coagulation (DIC).
Methods: This was a prospective monocenter cohort study of patients with septic shock. Von Willebrand Factor,
ADAMTS13-related parameters and plasma IL-6 concentration were measured at inclusion to the study. Patients
were categorized into three groups according to the presence of ADAMT13 deficiency (<30%) or DIC.
Results: This study included 72 patients with a median age of 59 years (interquartile range (IQR) 50 to 71). Each of
the included patients received vasopressors; 55 (76%) were under mechanical ventilation and 22 (33%) underwent
renal replacement therapy. Overall, 19 patients (26%) had DIC, and 36 patients had ADMTS13 deficiency (50%).
Patients with DIC, ADAMTS13 deficiency or both were more severe at ICU admission. Mortality was higher in septic
shock patients from group one. By multivariate analysis, Simplified Acute Physiology Score 2 (SAPS2) score (odds
ratio (OR) 1.11/point; 95% CI 1.01 to 1.24) and ADAMTS13 activity <30% (OR 11.86; 95% CI 1.36 to 103.52) were
independently associated with hospital mortality. There was no correlation between ADAMTS13 activity and the
International Society for Thrombosis and Haemostasis (ISTH) score (rs = −0.97, P = 0.41) suggesting that ADAMTS13
functional deficiency and DIC were independent parameters. IL-6 level was higher in patients with ADAMTS13
activity <30% [895 (IQR 330 to 1843) pg/mL versus 83 (IQR 43 to 118), P = 0.0003).
Conclusions: Septic shock was associated with a functional deficiency of ADAMTS13, independently of DIC.
ADAMTS13 functional deficiency is then a prognostic factor for mortality in septic shock patients, independently
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Sepsis is most frequently associated with hemostasis ab-
normalities [1-3], especially disseminated intra-vascular
coagulation (DIC). DIC is characterized by the associ-
ation of systemic activation of coagulation, impairment
of anticoagulant pathways and inhibition of fibrinolysis
[4,5]. Manifestations of DIC, which is associated with
an increased mortality during sepsis, include bleeding
and microthrombi leading to organ failure [6]. Animal
studies and clinical trials reported that impairment of
several anticoagulant pathways, like Protein C [7,8], tis-
sue factor pathway inhibitor [9] or anti-thrombin [8],
could also occur during sepsis. Substitution therapy
with these factors has not been shown to improve sep-
sis outcome [10,11].
Beside coagulation disturbances, abnormalities of von
Willebrand factor (VWF), related to endothelial damage,
have been reported in sepsis patients during the last dec-
ade [12,13]. VWF is a multimeric glycoprotein crucial
for platelet adhesion and aggregation at the high shear
rates of blood flow present in the microcirculation. The
largest VWF multimers are the most adhesive to plate-
lets and thus, the most efficient for primary hemostasis.
Ultra-large VWF multimers (ULVWF) are physiologically
present in endothelial cells and platelets, but absent in
plasma. A metalloprotease, ADAMTS13 (a disintegrin and
metalloprotease with thrombospondin type 1 repeats,
member 13), specifically cleaves ULVWF multimers and
thus, regulates its adhesive function. A severe ADAMTS13
deficiency (activity <5%) either inherited or most often
acquired via specific autoantibodies, is the main actor
in the pathophysiology of thrombotic thrombocytopenic
purpura (TTP) [14,15]. TTP is a thrombotic microangiop-
athy (TMA) characterized by thrombopenia, mechanical
hemolytic anemia, organ failure and VWF-rich micro-
thrombi [16-18]. As a consequence of its implication on
VWF multimer synthesis, sepsis has been reported as one
of the factors that might trigger thrombotic microangiopa-
thy [19] and TTP is one of the differential diagnoses of
DIC. Some cases of ADAMTS13 deficiency have been re-
ported recently in adult patients with sepsis-induced DIC
and this ADAMTS13 deficiency was associated with acute
renal failure [20]. Later clinical studies, also in adults and
focusing on sepsis without DIC [21-25] or isolated DIC
not specifically related to sepsis [26], reported decreased
ADAMTS13 activity. Interestingly, some of these studies
[20,21,25,26] showed that partially decreased ADAMTS13
activity was associated with outcome. In pediatric pa-
tients with severe sepsis, ADAMTS13 deficiencies have
also been reported [27-29]. In one of the latter studies
focused on children with thrombocytopenia-associated
multiple organ failure, mortality was associated with re-
duced ADAMTS13 activity and, interestingly, with VWF-
rich microvascular thrombosis at autopsy [28]. Also, thisstudy demonstrated that plasma exchange, a source of ac-
tive ADAMTS13, was able to restore ADAMTS13 activity
and organ function [28].
Although these studies gave interesting insight into
ADAMTS13 levels during sepsis, clinical relevancy, prog-
nostic association and mechanisms of a potential defi-
ciency remain uncertain. We thus designed the current
prospective study with the primary objective to study the
interaction between ADAMTS13 and DIC during septic
shock and its impact on outcome. As a secondary object-
ive, we investigated the mechanisms for ADAMTS13
functional variations in this clinical context. DIC, VWF
and ADAMTS13 parameters were exhaustively analyzed
and correlated with clinical data in 72 patients with septic
shock prospectively enrolled from a single Medical ICU.Methods
Patients
This study was approved by the Ethics Committee of the
SRLF, the French Speaking Society of Critical Care
Medicine (Approval number SRLF-CE 07–188) and the
need for informed consent was waived according to
French Law. Every of the included patients, or patients'
next-of-kin were informed however, and none refused to
participate in this study. Seventy-two consecutive pa-
tients with septic shock were prospectively enrolled at
the Medical ICU of Saint-Louis Hospital, Paris, France,
between March 2007 and February 2008. Septic shock
was diagnosed according to the American College of
Chest Physicians/Society of Critical Care Medicine defi-
nitions [30]. Clinical data, including sex, age, blood cell
count, Simplified Acute Physiology Score II (SAPS II)
[31] and Logistic Organ Dysfunction (LOD) [32] scores,
requirement for mechanical ventilation or renal replace-
ment therapy, were analyzed. Five mL of citrated venous
blood were collected at day 1 of admission within
12 hours of the diagnosis of septic shock and before
medication. Platelet-poor plasma was obtained after two
centrifugations at 1200 g and frozen at −80°C until
testing.DIC diagnosis
DIC was diagnosed using the International Society for
Thrombosis and Haemostasis (ISTH) DIC score [33],
which has been prospectively validated in intensive care
patients [34]. The score ranges from 0 to 8. A score ≥5
is compatible with overt DIC in patients with an under-
lying disorder known to be associated with DIC. Calcula-
tion of the score requires only routine coagulation tests:
platelets count, assay of a fibrin-related marker, pro-
thrombin time and fibrinogen. D-dimers were used as a
fibrin-related marker. As the prothrombin index (PI) was
available instead of prothrombin time, we used the
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(that is, PI >70%: 0 points; 40 to 70%: 1 point; <40%: 2
points).
Laboratory methods
For VWF antigen measurement, plasma VWF antigen
(VWF:Ag) was quantified using the STA-Liatest VWF®
(Diagnostica Stago, Asnières, France) immunoturbidi-
metric assay [36]. Samples were compared to a normal
plasma pool and results were expressed as percentages
(normal range: 50 to 150%). For VWF multimeric distri-
bution, VWF multimer analysis was performed as previ-
ously described using standard sodium dodecylsulfate
(SDS)/agarose gel electrophoresis, followed by immuno-
blotting [37,38]. ADAMTS13 activity was determined
using the synthetic fluorescent substrate FRETS-VWF73
as previously described [39] (normal range: 50 to 150%). For
ADAMTS13 antigen measurement, plasma ADAMTS13
antigen was determined using the IMUBIND ADAMTS13
ELISA® kit (American Diagnostica, Stamford, CT, USA)
(normal range: 540 ± 190 ng/mL). ADAMTS13 auto-
antibodies were screened in all patients using the
TECHNOZYME ADAMTS13-INH ELISA® commercial
kit (Technoclone, Vienna, Austria) which allows titra-
tion of specific anti-ADAMTS13 immunoglobulin (Ig)G
(positive if >12 U/mL, according to the manufacturer’s in-
structions). In both patients in whom the titer of anti-
ADAMTS13 IgG was positive and/or whose ADAMTS13
activity was below the median, an inhibitor assay was per-
formed as previously described [40]. Plasma IL-6 was de-
termined using the Human IL-6 Quantikine ELISA kit
from R&D Systems (Minneapolis, MN, USA).
Statistical analysis
Data are reported as numbers (percentages) or medians
(IQR: 25th to 75th percentiles). Continuous variables
were compared using the Wilcoxon rank sum test and
proportions using the Fisher exact test. Hospital mortal-
ity was the outcome variable of interest. We performed
univariate logistic regression analysis to identify variables
that significantly influenced the likelihood of mortality,
as measured by the estimated odds ratio (OR) with the
95% CI. All variables have been tested in univariate ana-
lysis. Variables of interest were defined prior to study
initiation. Logistic regression analysis was then per-
formed to identify variables significantly associated with
hospital mortality, as measured by the estimated OR
with the 95% CI. Variables yielding P-values lower than
0.20 in the bivariate analyses were entered into backward
stepwise logistic regression models where hospital mor-
tality was the variable of interest. The critical P-value for
removal was 0.1. Co-linearity and interactions were
tested. The Hosmer-Lemeshow test was used to check
goodness of fit. Given the number of events, a maximumof three variables was allowed in the models. Overall
survival was estimated using the Kaplan-Meier method
then compared using the log-rank test. Analyses were
done using the Statview software package (SAS Institute,
Carry, NC, USA).Results
Baseline characteristics and clinical course
Out of 72 enrolled patients, 46 (64%) were men. Median
(IQR) age was 59 (50 to 71) years. Bacterial infection
was documented in 44 (61%) patients. SAPS II and LOD
scores at admission were 56 (45 to 71) and 7 (5 to 10),
respectively. Among the 72 patients, 46 had microbio-
logical documentation of their septic shock, including,
22 with pneumonia, 11 with pyelonephritis, 7 with colitis
and 6 with catheter-related infections. Pathogens involved
were Escherichia coli (n = 12), Streptococcus pneumoniae
(n = 11), Pseudomonas aeruginosa (n = 7), Streptococcus
species (n = 5), Staphylococcus aureus (n = 4) and miscel-
laneous (n =7), namely, Salmonella typhi (n = 2), Neisseria
meningitides (n = 2), Klebsiella pneumonia (n = 2) and
Acinetobacter baumannii (n = 1).
The ISTH score was >5 in 19 (26%) patients who
therefore had overt DIC. Among detectable values (in 68
patients out of 72), median ADAMTS13 activity was
30% (IQR 19 to 45, range 10 to 78) whereas ADAMTS13
activity was undetectable (<5%) in 4 patients out of 72.
Among these four latter patients, none had DIC and
VWF/ADAMTS13 parameters were not significantly dif-
ferent from the rest of the cohort; all of them required
mechanical ventilation and three of them died. In the whole
cohort, median ADAMTS13:Ag level was 487 ng/mL (IQR
406 to 654, range 216 to 1965) and median VWF:Ag level
was 516% (IQR 371 to 695, range 234 to 1194).
All patients received vasopressors, 55 (76%) were mech-
anically ventilated, and 22 (33%) underwent renal replace-
ment therapy. ICU and hospital mortality rates were
40.3% (29 deaths) and 54.2% (39 deaths), respectively.Respective influence of DIC and ADAMTS13 on clinical
presentation and prognosis
There was no correlation between ADAMTS13 activity
and the ISTH score (rs −0.97, P = 0.41), suggesting that
ADAMTS13 functional deficiency and DIC were inde-
pendent parameters. Comparison between patients with
DIC (n = 19) and those without DIC (n = 53) showed no
significant difference, especially in ADAMTS13 and
VWF. In contrast, comparison between patients with an
ADAMTS13 activity <30% (n = 36) and those whose
ADAMTS13 activity was > 30% (n = 36) exhibited a sig-
nificant difference for both persistent shock at day 3
(88% versus 41%, P = 0.0006) and mortality (74% versus
41%, P = 0.03) (Table 1).
Table 1 Comparison of biological parameters in patients













DIC 11 (31%) 8 (22%) 0.59
ISTH score 3 (2, 5) 3 (1, 4) 0.58
Platelet count, day 1 61 (27, 199) 136 (29, 191) 0.47
Platelet count <65 G/L 17 (47.2%) 20 (56%) 0.05
ADAMTS13:Ag, ng/mL 457 (374, 496) 533 (413, 680) 0.15
Positive anti-ADAMTS13 IgG 3 4 NA
Anti-ADAMTS13 inhibitor 0 0 NA
VWF:Ag, % 492 (369, 642) 560 (402, 700) 0.42
IL-6, pg/mL 895 (330, 1843) 83 (43, 118) 0.0003
Values are expressed as median and IQR for continuous variables and as
number and proportion for categorical variables. Continuous variables were
compared using the non-parametric Mann–Whitney U-test. Categorical
variables were compared using the χ2 test. P <0.05 was considered significant.
DIC, disseminated intravascular coagulation; ISTH: International Society for
Thrombosis and Haemostasis; ADAMTS13, a disintegrin and metalloprotease
with thrombospondin type 1 repeats, member 13; Ig, immunoglobulin;
VWF:Ag, von Willebrand Factor antigen; NA, statistical test not performed.
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prognosis
To respond to our primary objective focused on both
the interaction between DIC and ADAMTS13 and prog-
nosis, we decided to divide the cohort into three groups.
As shown in Table 2, among the 72 patients with septic
shock, 28 (39%) patients had no DIC and an ADAMTS
activity above the median (group 1); 33 (46%) patients
had either DIC (n = 8) or an ADAMTS13 activity below
the median (n = 25) (group 2), and 11 (15%) patients had
both DIC and an ADAMTS13 activity below the median
(group 3). Four patients had ADAMTS13 activity <5%.
Patients with both DIC and ADAMTS13 activity <30%
had higher SAPS II and LOD severity scores than other
patients (77 versus 62 and 48, respectively for SAPS II,
P = 0.01 and 13 versus 7 and 7, respectively P = 0.01 for
LOD). The more hemostatic abnormalities the patients
had, the lower the blood pressure was (group 1, 85 mmHg;
group 2, 80 mmHg; group 3, 72 mmHg) and the arterial
partial pressure of oxygen/inspired oxygen fraction (PaO2/
FiO2) ratio (group 1, 240; group 2, 140; group 3, 95). There
was a trend toward higher lactate level in group-3 patients
(6.4 mmol/L versus 3.0 in group-1 and 2.4 in group-2
patients, P = 0.06). Median IL-6 concentration significantly
increased across the groups (group 1, 78 pg/mL; group 2,
318 pg/mL; group 3, 1835 pg/mL, P = 0.004).
Outcomes
The need for mechanical ventilation and dialysis did not
differ among the three groups. However group-3 patientswithout prior chronic renal failure required dialysis more
frequently than other patients without prior chronic renal
failure (71.4%, 50% and 50%, respectively, P = 0.05). Per-
sistent shock at day 3 was more frequent in group-3 and
group-2 patients than in group-1 patients (100%, 78% and
38%, respectively, P <0.001). Group-3 patients were more
frequently hypothermic and had more frequent positive
blood cultures.
Influence of ADAMTS13 on outcome
ICU mortality and hospital mortality were significantly
higher in group-2 and −3 patients than in group-1 pa-
tients (Table 2, Figure 1).
A comparison between ICU survivors (n = 43) and
non-survivors (n = 29) is presented in Table 3. Univariate
analysis of biological parameters showed that mortality
was associated with ADAMTS13 activity <30%, higher
VWF:Ag level and higher IL-6 level. Results of the logis-
tic regression are reported in Table 4. Both SAPS II
score and ADAMTS13 activity lower than 30% were in-
dependently associated with hospital mortality.
Performance of ADAMTS13 activity for the prediction
of hospital mortality has also been assessed using re-
ceiver operating characteristic (ROC) curves. The area
under the curve was 0.74 (0.60 to 0.88), with 67% sensi-
tivity, 69% specificity, a Younden index of 0.36, a positive
predictive value of 0.67 and a negative predictive value
of 0.70.
Mechanisms for ADAMTS13 deficiency
Consumption of ADAMTS13 by high levels of its substrate,
VWF
Plasma VWF:Ag was not significantly different across the
three groups (group 1, 578%, group 2, 543%, group 3,
393%, P = 0.14) as well as between patients with
ADAMTS13 activity <30% and those with ADAMTS13 ac-
tivity >30% (Table 1). Whatever the patient group, the
VWF multimeric pattern was similar, systematically show-
ing the presence of ULVWF.
Synthesis/secretion defect of ADAMTS13, proteolytic
degradation of ADAMTS13
Overall, ADAMTS13:Ag was not correlated with ADAM
TS13 activity. Also, it was not significantly different as a
function of ADAMTS13 activity towards the 30% me-
dian (Table 1) or across the three groups.
Functional inactivation of ADAMTS13
Detection of anti-ADAMTS13 IgG was positive in seven
patients: three exhibited ADAMTS13 activity <30% (15%,
24%, and 26%, respectively) and four exhibited ADAMTS13
activity >30%. In all of them, no circulating inhibitor
could be detected. Similarly, the inhibitor assay was nega-
tive in all patients whose ADAMTS13 activity was <30%.
Table 2 Severity of disease at presentation and outcome according to the number of hemostatic abnormalities in 72
patients with septic shock
Median (IQR) or
number (%)
Group 1, n = 28
(no DIC or ADAMTS13
activity >30%a)
Group 2, n = 33
(either DIC or ADAMTS13
activity <30%a)
Group 3, n = 11
(both DIC and ADAMTS13
activity <30%a)
P-value
ISTH score 3 (2, 4) 3 (2, 5) 5 (5, 7) 0.01
ADAMTS13 activity 46% (39, 79) 24% (19, 54) 15% (9, 25) 0.002
Severity of disease
LOD score, day 1 7 (4, 9) 7 (6, 10) 13 (7, 14) 0.02
SAPS II score, day 1 48 (38, 65) 62 (47, 69) 77 (51, 95) 0.01
Systolic blood pressure, mmHg 85 (80, 91) 80 (67, 86) 72 (67, 76) 0.004
PaO/FiO2 240 (116, 300) 140 (110, 245) 95 (76, 127) 0.02
Lactates, mmol/L 2.6 (2.0, 5.6) 3 (1.9, 6.3) 6.4 (1.9, 16.5) 0.06
IL-6 concentration, pg/mL 78 (46, 126) 318 (94, 1003) 1,835 (500, 3,030) 0.004
Outcome
Need for mechanical ventilation 19 (68) 26 (79) 10 (91) 0.25
Persistent shock, day 3 10 (35.7) 26 (79) 11 (100) 0.001
Need for RRT 8 (28.6) 10 (30.3) 5 (45.3) 0.24
Continuous hemofiltration 2 (7.1) 6 (18.2) 4 (36.3) 0.09
Dotrecogrin alpha activated 2 (7.1) 0 0 0.19
Stress dose steroids 6 (21.4) 6 (18.2) 1 (9) 0.64
Length of ICU stay 5 (3, 13) 5 (3, 13) 6 (2, 15) 0.95
ICU mortality 6 (21.4) 18 (54.5) 5 (45.4) 0.02
Hospital mortality 28.6% 71% 75% 0.007
Values are expressed as median and IQR for continuous variables and as proportion for categorical variables. Continuous variables were compared using the
non-parametric Kruskall-Wallis test. Categorical variables were compared using thea χ2 test. P <0.05 was considered significant. The normal range for ADAMTS13
activity is 50 to 150%. a30% corresponds to the median of ADAMTS13 activity in the 72 patients with septic shock. DIC, disseminated intravascular coagulation;
ISTH: International Society for Thrombosis and Haemostasis; ADAMTS13, a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; LOD,
logistic organ dysfunction; SAPS II, Simplified Acute Physiology Score II; PaO/FiO2, arterial partial pressure of oxygen/inspired oxygen fraction; RRT, renal
replacement therapy.
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three groups (group 1, 78 pg/mL; group 2, 318 pg/mL;
group 3, 1835 pg/ml, P = 0.004) (Table 2) and clearly in-
creased from group 1 to 3. Interestingly, IL-6 level was
considerably higher in patients whose ADAMTS13 ac-
tivity was <30% than in patients with ADAMTS13 ac-
tivity >30% (median 895 (IQR 330 to 1843) pg/mL and
83 (IQR 43 to 118), P = 0.0003) (Table 1).
Discussion
Sepsis-induced organ failure is associated with a micro-
circulation damage process involving mainly platelet/
fibrin-thrombi supporting DIC. In some cases, the po-
tential addition of platelet/VWF thrombi due to an ac-
quired ADAMTS13 functional deficiency and leading to
so-called TMA-like lesions is highly suspected in clinical
arguments [41-43] but still remains debated in terms of
prognosis and pathophysiology. Furthermore, in most
studies published so far, the subtle combination of DIC
and TMA-like lesions has been difficult to establish be-
cause of the great heterogeneity of the sepsis cohorts
tested, involving mixed cases within the categories ofsystemic inflammation, sepsis, septic shock, and sepsis-
related multiple organ failure [20-26], some of them
complicated by DIC and others not. In the current
study, we focused on a cohort of 72 patients with septic
shock prospectively enrolled from a single ICU in order
to respond to two objectives: first, to analyze the inter-
action between DIC and ADAMTS13 and its impact on
prognosis, and second, to elucidate the pathophysio-
logical mechanisms for ADAMTS13 deficiency. The
strength of our study is to propose an approach based
on clinical practice supported by three groups to evalu-
ate the prognostic value of ADAMTS13 in sepsis: we
showed that septic shock outcome is associated with a
functional deficiency of ADAMTS13 together with an
increase of IL-6, independently of DIC.
In our cohort, the median of ADAMTS13 activity was
30%, which is in agreement with the literature [20-26] and
most patients (57/72 = 79%) exhibited partial ADAMTS13
functional deficiency (values <50%). DIC was present in 19
patients (26%). The overlap between DIC and ADAMTS13
activity <30% was present only in 11 patients (15%), sug-






Figure 1 Kaplan-Meier graph for cumulative survival according
to the number of hemostatic abnormalities (A) or according to
ADAMTS13 activity (B) in 72 patients with septic shock. Group 1:
no DIC and ADAMTS13 activity >30%; group 2: either DIC or
ADAMTS13 activity <30%; group 3: DIC and ADAMTS13 activity <30%:
30% corresponds to the median of ADAMTS13 activity in the 72
patients with septic shock. ADAMTS13, a disintegrin and
metalloprotease with thrombospondin type 1 repeats, member 13;
DIC, disseminated intravascular coagulation.
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between the ISTH score and ADAMTS13 activity and by
the lack of a significant difference in ADAMTS13 between
DIC-positive and DIC-negative patients and in the ISTH
score between patients with ADAMTS13 activity >30%
and <30%. Thus, the independence between DIC and
ADAMTS13 activity prompted us to divide our cohort
into three groups in order to compare patients with ab-
sence of both DIC and ADAMTS13 deficiency to other
patients. We observed that the higher the number of
hemostatic abnormalities, the higher the disease severity.
We also found a strong significant difference between
groups for all indicators of disease severity at ICU admis-
sion (LOD score, SAPS II score, systolic blood pressure,
PaO/FiO2, lactates, IL-6 concentrations) suggesting that
both isolated ADAMTS13 deficiency and DIC-associatedADAMTS13 deficiency were markers of severity in sepsis.
Only one study dedicated to ADAMTS13 in 40 septic pa-
tients analyzed disease severity scores (LOD and SAP
scores) but did not find any correlation with ADAMTS13
[23]: this discrepancy with our study may be related to the
presence of only eight patients with septic shock and no
cases of DIC [23].
Furthermore, in our study, there was also significant
correlation between the number of hemostatic abnor-
malities and some outcome indicators that is, persistent
shock at day 3. The need for dialysis, reflecting renal
failure, was not significantly different between the three
groups although the association of both DIC and
ADAMTS13 deficiency <30% exhibited more renal fail-
ure than both of the other groups with a borderline sig-
nificance (P = 0.05). These data are in agreement with
other studies of the literature led in adult patients
[20,21,24-26]: indeed, our group 3 is strongly compar-
able to the 109 patients with sepsis-induced DIC de-
scribed by Ono et al. [20] who also found a higher rate
of renal failure in patients whose ADAMTS13 activity
was <20%. Also, Martin et al. [21] demonstrated that in
30 patients with severe sepsis, including 17 patients with
septic shock and 4 patients with DIC, ADAMTS13 activ-
ity <30% was correlated with renal failure and as in our
study, with hemodynamic shock. Other studies involving
patients with severe sepsis/septic shock [24-26] also
found a correlation between ADAMTS13 activity and
organ dysfunction, in contrast to Kremer et al. [23].
Finally, our study demonstrates that DIC and ADAMTS13
deficiency <30% are independent markers of mortality
in septic shock, particularly as the mortality rate is
strongly dependent on the position of the ADAMTS13
level towards the median value (significantly higher mor-
tality rate when ADAMTS13 is <30%) and ADAMTS13
deficiency appears to be a potential prognosis marker.
Although prognostic association between ADMATS13
deficiency and outcome remains after adjustment for
confounders, the diagnostic performance of this test re-
mains modest. In addition, confirmation of our findings
in a validation cohort is needed. To corroborate this
observation, both ICU and mortality rates were not sig-
nificantly different in group-2 (mainly including iso-
lated ADAMTS13 deficiencies) and group-3 patients.
In other words, in our cohort, the addition of DIC to
ADAMTS13 deficiency did not significantly change the
mortality rate. Again, these data are in agreement with most
studies of the literature [20,21,24-26]. Interestingly, in our
cohort, four patients exhibited ADAMTS13 activity <5%. A
previous study in 109 patients with sepsis-induced DIC
also found that 17 patients had severe ADAMTS13 func-
tional deficiency [20], and also exhibited a TTP-like clin-
ical presentation. The mechanism by which some septic
patients reach a severe ADAMTS13 deficiency similar to
Table 4 Factors independently associated with hospital
mortality (conditional backward stepwise regression
model)
Odds ratio 95% CI P-value
SAPS II score, per point 1.11 1.01, 1.24 <0.0001
ADAMTS13 activity <30% 11.86 1.36-103-52 0.0004
SAPS II, Simplified Acute Physiology Score II; ADAMTS13, a disintegrin and
metalloprotease with thrombospondin type 1 repeats, member 13.
Table 3 Comparison of biological parameters between survivors and non survivors (ICU mortality) of the septic shock
cohort (n = 72)
Survivors Non-survivors P-value
(n = 43) (n = 29)
Disseminated intravascular coagulation (DIC) 10/43 (23%) 9/29 (31%) 0.59
ISTH score 3 (1, 4) 4 (2, 5) 0.67
Platelet count, G/l 65 (20, 184) 87 (47, 195) 0.30
ADAMTS13 activity <30% 17/43 (37%) 19/29 (66%) 0.05
ADAMTS13 activity <5% 1/43 3/29 -
ADAMTS13:Ag, ng/mL 483 (384, 613) 491 (418, 696) 0.24
VWF:Ag, % 477 (341, 656) 560 (478, 835) 0.05
IL-6, pg/mL 107 (48, 418) 840 (204, 1089) 0.03
Values are expressed as median and interquartile range for continuous variables and as number and proportion for categorical variables. Continuous variables
were compared using the non-parametric Mann–Whitney U-test. Categorical variables were compared using the χ2 test. P <0.05 was considered significant.
ISTH, International Society for Thrombosis and Haemostasis; ADAMTS13, a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13;
ADAMTS13:Ag, ADAMTS13 antigen; VWF:Ag, von Willebrand Factor antigen.
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have an important impact on prognosis.
The association between functional partial deficiency of
ADAMTS13 and clinical prognosis factors in sepsis raises
the question of the relevance of this metalloprotease as a
passive marker or, in contrast, as an actor in the patho-
physiology of organ failure. First, normal ADAMTS13:Ag
levels found in our cohort suggested that ADAMTS13
functional deficiency was mainly related to a qualitative
defect and not to a quantitative defect secondary to a
synthesis/secretion deficiency or to a degradation process
mediated by sepsis-related enzymes [20,44-48]. Second,
direct catalytic inhibition of ADAMTS13 by IL-6, a cyto-
kine highly secreted in sepsis, has been reported in vitro
using ULVWF strings secreted from human umbilical vein
endothelial cells under flowing conditions [49]. Clinical
studies focused on septic patients are controversial, show-
ing either no correlation between ADAMTS13 activity
and IL-6 levels [23] or in contrast, a strong inverse correl-
ation between these parameters [21,24]. Interestingly,
in the current study, we also found a strong inverse
correlation between ADAMTS13 activity and IL-6
levels. Although this inverse correlation does not allow ex-
trapolation of any causal relationship, this result suggests
a potential role of IL-6 in the functional deficiency of
ADAMTS13 observed in septic shock. Additional studies
are needed to confirm these findings and to more clearly
assess the role of IL-6 on ADAMTS13 activity. Also, in
our study, the link between IL-6 levels and prognosis
already reported by other authors [50] may be mediated
by ADAMTS13 deficiency. In contrast, no relevant spe-
cific autoantibodies to ADAMTS13 were detected,
making unlikely the involvement of an autoimmune
process in sepsis-associated ADAMTS13 functional de-
ficiency. Third, in all our patients, we found increased
VWF:Ag levels and the presence of UL-VWF multimersin plasma. An overwhelming release of ULVWF multimers
from activated endothelial cells may exhaust ADAMTS13
activity by a consumption mechanism [44,46,49-54]. In
septic patients, the literature is controversial either sup-
porting this consumption process [20,21,24,25] or not
[23]. Further studies are needed to confirm prognostic im-
pact of ADAMTS13 deficiency and to validate a cutoff for
ADAMTS13 activity that may be used to assess outcomes,
independently of other determinants of death.
Our study has several limitations. First, our study does
not include any control group. Indeed, without this con-
trol group we do not know whether the current findings
are specific to septic shock and whether the observed re-
lationship (or lack thereof ) is similar to the relationship
in critically ill patients who do not have septic shock. In
addition, the compared group had, as expected, different
severity at study inclusion. However, the prognostic im-
pact persisted after adjustment for patient severity, sug-
gesting the prognostic association between ADAMTS13
deficiency and outcome to be independent from initial
severity differences.
Conclusion
Our study underlines that septic shock seems to be asso-
ciated with partial functional deficiency of ADAMTS13,
which mechanism is potentially related to IL-6-mediated
inhibition but is independent of DIC. As a consequence,
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cleared from the circulation and generate spontaneous
formation of microvascular platelet thrombi responsible
for multivisceral organ failure. Last but not least, our
study emphasizes the role of ADAMTS13 as a prognosis
factor in septic shock. These data are in agreement with
the exciting concept of ADAMTS13 as a link between
inflammation and thrombosis, which was recently devel-
oped thanks to animal models [55-58]. In addition, this
study may bring new insights in the field of hemostasis
inhibitor-based treatment in severe sepsis: indeed, although
the efficiency of coagulation inhibitors is still controversial
[59], downregulation of VWF-mediated thrombosis by ex-
ogenous ADAMTS13 brought by plasma infusions, or in
the future by plasma-purified or recombinant ADAMTS13,
may be an interesting new approach targeted on primary
hemostasis.
Key messages
 Septic shock seems to be associated with partial
functional deficiency of ADAMTS13, which
mechanism might be related to IL-6-mediated
inhibition.
 ADAMTS13 is an independent prognostic factor
during septic shock.
 No correlation was observed in this study between
ADAMTS13 deficiency and DIC.
 ADAMTS13 deficiency may decrease clearance of
excessively released ULVWF multimers, leading to
spontaneous microvascular platelet thrombi
formation and multiple organ failure.
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